Iambic Therapeutics (IAM) Stock Analysis

What Iambic Therapeutics does

Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.

Key metrics

ETFs linked to IAM

Broad-market and Healthcare sector ETFs an investor holding Iambic Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how IAM fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Iambic Therapeutics?

Iambic Therapeutics trades under the ticker IAM on NASDAQ.

Which exchange is IAM listed on?

IAM is listed on NASDAQ.

What sector does Iambic Therapeutics operate in?

Iambic Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze IAM in a portfolio?

PortView shows IAM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.